NCT05252364View on ClinicalTrials.gov

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

January 22, 2024

Study Completion Date

January 22, 2024

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

HP518 - Dose Escalation

"Part 1: Dose escalation~Daily oral dosage with the prescribed dose level based on Cohort assignment."

DRUG

HP518 - Dose expansion

"Part 2: Dose expansion~Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1."

Trial Locations (5)

2050

Chris O'Brien Lifehouse, Camperdown

2113

Macquarie University, Macquarie Park

2640

Border Medical Oncology, Albury

3000

Peter McCallum Cancer Center, Melbourne

3181

Alfred Hospital, Melbourne

Sponsors
All Listed Sponsors
lead

Hinova Pharmaceuticals Aus Pty Ltd

INDUSTRY

NCT05252364 - A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter